Elligo Health Research Partners with Austin Cancer Center
Elligo Health Research, a healthcare-enabling research organization, announced its partnership with Austin Cancer Center (ACC), an independent oncology group in central Texas. The partnership expands Elligo’s Research Ready network to include its first oncology practice, broadening Elligo’s therapeutic specialization and allowing ACC’s oncologists to offer research as a care option. ACC is currently enrolling patients for studies in breast cancer.
“Partnering with Elligo allows us to bring cutting-edge capabilities to our patients,” said Blayne Rush, MBA, ACC’s CEO. “We’re excited they can remain under our care while benefiting from the innovative treatments available through participation in clinical studies.”
“Bringing the Research Ready network to cancer patients in this area is a milestone achievement in our promise to preserve the trusted patient and physician relationship and unite the best clinical experts with the best research infrastructure,” said John Potthoff, PhD, Elligo’s CEO.
Learn more at elligodirect.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
